Correspondence 0000950170-23-010319 from Virax Biolabs Group Ltd (VRAX) (CIK 0001885827) (VRAX)
Virax Biolabs Group Ltd (VRAX) (CIK 0001885827)
Date: March 28, 2023 · CIK: 0001885827 · Accession: 0000950170-23-010319
AI Filing Summary & Sentiment
File numbers found in text: 333-270734
Letter
Virax Biolabs Group Limited
20 North Audley Street
London, W1K 6LX
United Kingdom
VIA EDGAR
March 28, 2023
U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn: Lauren Hamill
Re:
Virax Biolabs Group Limited
Registration Statement on Form F-1
Filed March 22, 2023
File No. 333-270734
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m., Eastern Time, on March 30, 2023, or as soon as thereafter practicable.
Very truly yours,
/s/ James Foster
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Virax Biolabs Group Limited
20 North Audley Street
London, W1K 6LX
United Kingdom
VIA EDGAR
March 28, 2023
U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn: Lauren Hamill
Re:
Virax Biolabs Group Limited
Registration Statement on Form F-1
Filed March 22, 2023
File No. 333-270734
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m., Eastern Time, on March 30, 2023, or as soon as thereafter practicable.
Very truly yours,
/s/ James Foster
James Foster
Chief Executive Officer
DOCPROPERTY "DocID" \* MERGEFORMAT 23722827.1
240437-10005